ESMO Breast 2024 Insights: "FeDeriCa Trial Final Analysis - Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection + Chemo in HER2+ eBC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ESMO Breast 2024 Insights: "FeDeriCa Trial Final Analysis - Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection + Chemo in HER2+ eBC"

By Insights from ESMO Breast 2024 Annual Meeting FEATURING Christian Jackisch

0 views

June 21, 2024

Comments 0

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo